Diabetes mellitus

Regulation of glucose metabolism

Insulin a ins. sensitivity vs. resistance

Classification of DM

PP of primary types of DM – T1DM and T2DM

Acute and chronic complications of DM

Definition of diabetes mellitus (DM)

- DM is a group of metabolic disorders characterized by **hyperglycemia** resulting from a lack of insulin effect
    - due to either defect in insulin secretion or insulin action

- **chronic hyperglycemia** leads to long-term cell, tissue & organ damage = **diabetic complications**
    - retina
    - kidney
   - nerves

Fasting vs. absorptive state


Fasting man
(24 hours basal–1800 cal)

Origin of fuel

Muscle Protein 75g → Amino acids → Liver

Adipose tissue Triglyceride 160g → Fatty acid 160g
Glycerol 16g

Liver: Glycogen, Gluconeo-genesis, O_2, H_2O, ~P, Ketone 60g, 40g, ?

Fuel consumption

Glucose 180g 144g → Nerve O_2 ~P $CO_2 + H_2O$
36g → RBC, WBC, etc ~P
36g ← Lactate + pyruvate

Heart Kidney Muscle etc O_2 ~P $CO_2 + H_2O$
(Fatty acid) 120g

Major metabolic thrust: anabolism and energy storage

Amino acids / Glycerol and fatty acids / Glucose → Proteins / Triglycerides / Glycogen

Major energy fuel: glucose (dietary)

Glucose → $CO_2 + H_2O$ + ATP

Liver metabolism: amino acids deaminated and used for energy or stored as fat

Amino acids → Keto acids (in liver) → Fats / $CO_2 + H_2O$ + ATP

(a) Major events of the absorptive state

In muscle: Glycogen ← Glucose → Protein
In all tissues: Glucose → $CO_2 + H_2O$ + ATP

Gastro-intestinal tract → Amino acids, Glucose, Fats

In liver: Keto acids → Protein, $CO_2 + H_2O$ + ATP, Fatty acids → Fats; Glyceraldehyde-phosphate → Glycerol → Fats; Glycogen

In adipose tissue: Glucose → Fatty acids, Glycerol → Fats; Fatty acids → Fats

(b) Principal pathways of the absorptive state

Copyright © 2001 Benjamin Cummings, an imprint of Addison Wesley Longman, Inc.

MUNI MED

Regulation of glycemia

- humoral
  - principal
    - **insulin**
    - **glucagon**

  - auxiliary
    - glucocorticoids
    - adrenalin
    - growth hormone
- neural
  - sympaticus
    - hyperglycemia

 - parasympaticus
    - hypoglycemia

FOOD

glykogenolysis

PRODUCTION of GLUCOSE by LIVER

glukoneogeneze
- pyruvát
- laktát
- aminokyseliny
- glycerol

INSULIN

plasma
(glycaemia
3–6 mmol/l)

GLUCAGON

MUSCLE, ADIPOSE TISSUE

inzulin-dependent utilisation

non-inzulin-dependent utilisation

CNS A OTHER TISSUES

MUNI
MED

What happens (in healthy man) after meal = insulin orchestrates allocation and utilisation of nutrients

diabetic "triumvirate"

⭐ What happens (in healthy man) after meal = insulin orchestrates allocation and utilisation of nutrients


- liver
  - stimulation of glycogen formation (up to~ 5% of liver weight)
    - ↑ hexokinase, phosphophructokinase, glycogensynthase
    - ↓ G-6-P-kinase
  - inhibition of gluconeogenesis
    - ↓ PEPCK
  - fat formation
    - ↑ synthesis of FFA and VLDL
  - proteosynthesis
    - ↑ transport of AA
  - inhibition of ketogenesis
- muscle
  - translocation of GLUT4
  - formation of glycogen
  - proteosynthesis
    - ↑ transport of AA
- adipose tissue
  - translocation of GLUT4
    - Glc → glycerol
  - stimulation of adipogenesis
    - ↑ activity of LPL
      - hydrolysis of VLDL and resynthesis of TAG
    - ↓ hormone-sensitive lipase
- brain
  - insulin participates in the control of appetite/satiety

Diagnosis of DM

- diabetes
  - classical symptoms + random plasma glycemia ≥11.1 mmol/l (venous plasma)
    - random = any time of the day
    - symptoms include polyuria and polydipsia
  - FPG (fasting plasma glucose) ≥7.0 mmol/l
    - fasting means at least 8 h from the last meal
  - 2-h PG (postprandial glucose) ≥11.1 mmol/l during oGTT
    - oGTT: according to the WHO consists of FPG examination followed by a standard load of 75g of glucose (diluted in water) and examination of glycemia in 60th and 120th minute
- impaired glucose tolerance (IGT)
  - excluded <7.8 mmol/l
  - 2-h PG ≥7.8 - <11.1 mmol/l during oGTT
- impaired fasting glucose (IFG)
 - diabetes excluded by FPG ≤5.6 mmol/l
  - FPG ≥5.6 – <7 mmol/l

Importance of fasting plasma glucose measurement

an intensity of liver glucose production is a very sensitive „marker" of insulin sensitivity

MUNI
MED

Q1: The way glucose enters the cell??

# INSULIN SECRETION VS. INSULIN SENSITIVITY / RESISTANCE

Insulin – world diabetes day

- 14/11 (od 1991)
- birthday of the man who co-discovered insulin, Frederick Banting
- Banting discovered insulin in 1922 alongside Charles Best under the directorship of John McLeod and with assistance of James Collip
- The Nobel Prize in Physiology or Medicine 1923 was awarded jointly to Frederick Grant Banting and John James Rickard Macleod "for the discovery of insulin"

Insulin

- exocytosis from B-cells of islets of Langerhans into portal circulation
  - 50% degraded during first pass through liver
  - parallel cleavage of the C-peptide
- total daily production in healthy subject ~20-40 U
  - 1/2 **basal** (postabsortive) secretion
    - pulsatile (5 - 15 min intervals)
  - 1/2 **stimulated** (postprandial)
    - early phase (ready insulin)
      - Glc/K_{ATP}-dependent
    - late phase (synthesis de novo)
      - other secretagogues
- stimulation of secretion
  - <<<glucose
  - <<amino acids
  - <GIT hormones (incretins)
  - FFA
    - variable stimulation (length of chain & (un)saturation)!!
    - since insulin is acting also as peripheral "satiety" signal, reaching the satiety is delayed after fatty meal

Insulin synthesis

Langerhans islets - architecture

- The pancreatic islet blood flow is 5–10 times higher than that of the exocrine pancreas, and can be selectively enhanced whenever the need for insulin secretion is increased

- B-A-D flow hypothesis

   - that is why contra-regulation insulin/glucagon works so well

C peptide

- activity
  - certain beneficial vascular effects (nitric oxide)
- mainly diagnostic use
  - equimolar to insulin
  - unlike insulin, C-peptide is not degraded from portal blood in liver
 - the systemic concentration reflects endogenous insulin production

# Coupling: glycemia – insulin secretion

Hexokinase vs. glucokinase

- **hexokinase** (ubiquitously with exception of liver and pancreatic b-cells)
  - activity increases with increased glucose but activity is inhibited by increased G6P
  - levels of enzyme are constitutive
  - only generates ATP when energy is required
- **glucokinase** (hepatocytes and b-cells)
  - is not normally active because its Km is lower than normal blood glucose levels
  - eating food increases glu in blood, activates glucokinase which converts glu to glycogen and fatty acids
  - activity increases with increased glucose but is not inhibited by increased glu6PO4
  - the levels of the protein are regulated by insulin
  - rate of reaction is driven by substrate-glucose not by demand for product-G6P
    - allows all glu available to be converted to G6P and then if excess present, it is converted to glycogen and from there to triglycerides and fatty acids

Insulin Secretion is Biphasic

Phase 1

Insulin Release

Minutes

0 5

Mobilization (slow phase)

ATP

ATP   Ca⁺⁺

Phase 2

Docking and energizing

Membrane fusion and hormone release (fast phase)

High glucose levels

Insulin secretion

1st phase

2nd phase

Basal

0 ~5 min

Time

- in vivo not so obvious
  - 1. phase – Glc/K_{ATP}-dependent
 - 2. phase – other secretagogues

NEFA and insulin secretion

- NEFA can enter cells (incl. B-cells)
    - directly by diffusion across the membrane (short-chain FA) → metabolism (oxidation) → ATP .... insulin secretion
    - via receptor (GPR40) → see the figure
- however, long term exposure to NEFA, esp. long-chain saturated (e.g. palmitate), suppress secretion of insulin and damages B-cells

Incretins – enteroinsular axis

- GIT hormones produced by endocrine cells of small intestine stimulating insulin secretion even **before elevation of blood glucose**
  - Ins-secretion after oral Glc >> after i.v. Glc
    - hypoglycemia – if the patient still conscious then better to give Glc per os
- "forward" regulatory mechanism – anticipation of increase of Glc
- 2 major incretin hormones
  - GIP (glucose-dependent insulinotropic peptide or gastric inhibitory peptide)
  - GLP-1 (glucagon-like peptide-1)
- treatment of T2DM [= delayed effect of Glc on Ins stimulation] by incretin analogues
  - GLP-1 analogue - exenatide (GLP-receptor agonist)
  - DPP-4 inhibitors (dipeptyl peptidase 4 - proteolytic degradation of incretins) - gliptins
  - improvement of Glc-stimulated Ins secretion after meal
  - supression of postprandial glucagon release
 - delayed gastric emptying
 - protection of β-cells from apoptosis

Gila monster

Effect of GLP-1 – anticipation of need to rise insulin

Incretins have systemic effects too

Increasing plasma GLP-1 concentrations

Reduced food intake

Delays gastric emptying

Stimulation of insulin secretion
Inhibition of glucagon secretion
Increased β-cell mass?

GLP-1 during
GLP-1 receptor
agonist treatment

GLP-1 during
DPP-4 inhibitor
treatment

Reduced plasma glucose
Reduced insulin dose
Weight loss

MUNI
MED

INSULIN SIGNALLING

Insulin receptor

Insulin receptor made simple

- insulin receptor is a **tyrosinkinase** type (2 α and 2 β subunits) receptor
- signal transduction consists of series of phosphorylation events
  - intracellular proteins, other kinases and finaly enzymes
    - i.e. their activation or inhibition
      - activation of anabolic pathways (i.e. glycegenogenesis, lipogenesis)
      - inhibition of catabolic pathways (e.g. lipolysis, glycogenolysis) and gluconeogenesis
- two main effects happen in insulin-dependent tissues
  - (1) $\uparrow$ glucose uptake
    - by translocation of GLUT4 in sceleatl muscle and adipose tissue
  - (2) metabolic: IRS $\rightarrow$ PI-3-K $\rightarrow$ PDK $\rightarrow$ PKB (=Akt)
    - $\rightarrow$ GSK (glycogen-synthase-kinase) $\rightarrow$ $\uparrow$ glycogen synthesis
    - $\rightarrow$ cAMP phosphodiesterase $\rightarrow$ inhibition of lipolysis
    - $\downarrow$ gluconeogenesis
- ubiquitously (3) $\uparrow$ gen. expression (mitogenic effect)
  - MAPK $\rightarrow$ transcription factors

Classification of tissues according to insulin action:

- **insulin-dependent**
  - **skeletal and heart muscle**
  - **adipose tissue**
    - in both glucose uptake facilitated by **GLUT4**, which becomes integrated into cell membrane after insulin receptor activation


  - **liver**
    - metabolic actions

- **insulin-independent**
  - **all others**
    - glucose uptake is realized by facilitated diffusion by **GLUT1, 2, 3, 5, …** permanently localized in the cell membrane
    - transport of glucose depends solely on
      - concentration gradient
      - type and density of GLUTs
    - **NOTE skeletal and heart muscle, adipose and liver also express insulin-independent GLUTs**

Insulin sensitivity – a hyperbolic relation between i. secretion and sensitivity

Insulin secretion (pmol per min) vs Insulin sensitivity M value (μmol/min per kg)

- Insulin sensitivity refers to the body's ability to dispose of glucose
  - x-axis represents the amount of glucose cleared at a given insulin dose
- A variety of evidence has shown that active individuals clear greater glucose with lower insulin secretion than sedentary individuals
  - that is, active individuals are more insulin sensitive
  - becoming inactive and or obese makes you insulin resistant
- As sedentary individuals become progressively more insulin resistant, pancreatic beta cells hypertrophy and eventually become unable to secrete sufficient insulin to clear glucose from the blood after a meal
- This end state is referred to as glucose intolerance

Insulin sensitivity assessment

- insulin sensitivity (= given effect of dose of insulin on individual's glycaemia) is a continuous trait
- distinct interindividual variability
- it can be assessed by:
  - hyperinsulinemic euglycemic clamp
  - calculated indexes (based on relationship between glycaemia and insulin during fasting or oGTT)
    - e.g. HOMA, QUICKI, …
- insulin sensitivity changes (= **insulin resistance**) in many situations
  - physiologically in pregnancy
  - pathologically in obesity, inflammation etc.
- **should increasing insulin resistance always lead to compensatory increase of insulin secretion than glycaemia would stay stable**
  - however capacity to compensatory increase secretion of insulin by beta-cells is apparently limited

Frequent blood sampling

Glucose Analyzer

Adjust glucose infusion rate to "clamp" blood glucose levels

"Steady State" Glucose Infusion Rate =Net Glucose Utilization

Hepatic Glucose Production

Plasma Glucose

Glucose Disposal

Plasma Insulin

Constant Insulin Infusion

CLASSIFICATION OF DM, T1DM A T2DM

Pathophysiology of diabetes mellitus

- **heterogeneous** syndrome characterized by **hyperglycemia** due to **deficiency of insulin action** as a result of
  - absolute insulin deficiency
    - **destruction of the β-cells of the islets of Langerhans**
  - relative deficiency of insulin secretion and/or action
    - abnormal molecule of insulin (mutation of insulin gene)
    - defective conversion of preproinsulin to insulin
    - circulating antibodies against insulin or its receptor
    - **insulin resistance in peripheral tissues + secondary failure of β-cells of the islets of Langerhans**
      - receptor defect
      - **post-receptor defect**
- prevalence of DM in general population 5%, over the age of 65 already 25%

Prevalence (%) of diabetes (population 20-79 years)

2010 – 4.3 bil. (from a total of 7 bil.)

285 mil. diabetics

0.75 mil. diabetics in Czech rep.

2030 – 5.6 bil. (from a total of 8.5 bil.) 30%

438 mil. diabetics 54%

1.2 mil. diabetics in Czech Rep. 60%

MAP 2.1   Prevalence* (%) estimates of diabetes (20-79 years), 2010

<4%
4 - 5%
5 - 7%
7 - 9%
9 -12%
>12%

* comparative prevalence

IDF Diabetes Atlas, 4th ed. © International Diabetes Federation, 2009

MAP 2.2   Prevalence* (%) estimates of diabetes (20-79 years), 2030

<4%
4 - 5%
5 - 7%
7 - 9%
9 -12%
>12%

* comparative prevalence

IDF Diabetes Atlas, 4th ed. © International Diabetes Federation, 2009

[IDF Diabetes Atlas, 4th ed. ©International Diabetes Federation, 2009]

MUNI
MED

Classification of DM

- **Diabetes mellitus type 1 (T1DM) ~5%**
- **Diabetes mellitus type 2 (T2DM) ~90%**
- **Gestational diabetes mellitus (GDM) ~10 - 15% of pregnant women**
- **Monogenic DM ~2%**
  - neonatal
  - MODY (1 - 6)
- **Secondary**
  - diseases of exocrine pancreas
    - chron. pancreatitis, tumor, cystic fibrosis, hemochromatosis
  - endocrine disorders (insulin contra regulation)
  - Cushing syndrome, acromegaly, pheochromocytoma, hyperthyreosis
- **Drug induced** (iatrogenic) DM
  - glucocorticoids and others
- Other forms (syndromic)
  - mutation of mitochondrial DNA
  - genetic defects leading to insulin resistance (type A insulin resistance, leprechaunismus, Rabson-Mendenhal syndrome, lipoatrophic DM)
  - other genetic syndromes associated with DM (m. Down, Klinefelter, Turner)

Classification of DM

1. Diabetes mellitus type 1 (T1DM) ~5%
2. Diabetes mellitus type 2 (T2DM) ~90%

3. Other specific types:
 	
a. genetic defects of B-cell
  - monogenic DM (MODY1 - 6)
  - mutation of mitochondrial DNA
b. genetic defects leading to insulin resistance
  - type A insulin resistance, leprechaunismus, Rabson-Mendenhal syndrome, lipoatrophic DM
c. diseases of exocrine pancreas
  - pancreatitis, tumor, cystic fibrosis, hemochromatosis
d. endokrinopathies
  - Cushing syndrome, acromegaly, pheochromocytoma, hyperthyreosis
e. iatrogenic DM (i.e. drugs and toxins)
f. other genetic syndromes associated with DM
  - Down, Klinefelter, Turner syndromes, …

4. Gestational diabetes mellitus

T2DM

From insulin resistance to T2DM

- insulin sensitivity changes (= **insulin resistance**) in many situations
  - physiologically in pregnancy
  - pathologically in obesity, inflammation etc.
- **should increasing insulin resistance always lead to compensatory increase of insulin secretion than glycaemia would stay stable**
  - however capacity to compensatory increase secretion of insulin by beta-cells is apparently limited
- main pathophysiologic feature of T2DM is an imbalance between insulin secretion and its effect
  - **in the time of clinical manifestation there are both insulin resistance and impairment of insulin secretion**
- **what is "chicken" and what is "egg"??**
  - see later T2DM genetics

MUNI
MED

What determines insulin resistance and/or insulin secretion?

- insulin resistance
  - genetic predisposition (polygenic) – thrifty genotype/phenotype
  - acquired factors
    - diet – high fat/low fiber
      - competition of Gls with NEFA!!!
    - **obesity – 90% T2DM are obese**
      - effect of adipokines from adipose tissue (visceral!)
      - low-grade inflammation
      - lipid spillover – competition with Glc
      - several other mechaisms
    - physical inactivity - ↓ mobilization of GLUT4
    - down-regulation of ins. receptor due to hyperinsulinemia

- impairment of insulin secretion
  - inherited factors - genetics
    - fewer B-cells (~20-40%)
    - defect of 1. phase of Ins secretion (~80% reduction)
  - acquired factors
    - – gluco- and lipotoxicity for B-cells

Metabolic syndrome – a unifying effect of obesity

Genetics of T2DM

Grouped T2DM susceptibility loci

Group 1	
• ABO	• MTNR1B
• ADCY5	• SLC30A8
• GCK	• TCF7L2
• HNF1A	• TMEM258

↓ Fasting insulin
↓ HOMA-B
↑ Proinsulin

Group 2	
• ADAMTS9	• HMG20A
• ANK1	• IGF2BP2
• C2CD4A-B	• JAZ1
• CCND2	• KCNJ11
• CDKAL1	• KCNQ1
• CDKN2A-B	• KLHDC5
• CENTD2	• PROX1
• DGKB	• THADA
• GLIS3	• ZBED3
• GPSM1	• ZHX3
• HHEX-IDE	

↓ Fasting insulin
↓ HOMA-B
↓ Proinsulin

Group 3		
• BCAR1	• HORMAD2	• RREB1
• BCL11A	• MHC	• SPRY2
• CDC123/CAMK1D	• MLX	• TLE1
• CENPW	• MPHOSPH9	• TMEM154
• CEP68	• MRAS	• TPCN2
• FAM63A	• MTMR3	• TSPAN8
• GIPR	• PAM	• TTLL6
• GIPR	• PAX4	• WFS1
• HMGA2	• PIM3	• WSCD2
• HNF1A	• PLEKHA1	• ZMIZ1
• HNF1A	• PNPLA3	• ZZEF1
• HNF1B	• PRC1	
• HNF4A	• PTPN9	

Defects in both insulin secretion and insulin action

- Genome-wide association studies (GWAS) have identified over 400 genetic signals that are associated with altered risk of T2DM. Human physiology and epigenomic data support a central role for the pancreatic islet in the pathogenesis of T2DM

MUNI
MED

Genetics of T2DM – a spectrum of impairments

Predominantly insulin deficient monogenic T2DM
Mutations in HNF-1α, HNF-4α, HNF-1β, IPF, NEUROD-1,
mitochondrial DNA, insulin genes

Impairment in insulin secretion

Polygenic type 2
diabetes

Decrease in insulin sensitivity

Predominantly insulin resistant monogenic T2DM
Mutations in insulin receptor, PPARγ, AKT-2 genes

Natural history of T2DM – time course

Natural history of T2DM – disease mechanisms

Insulin- and "sport"-dependent translocation of GLUT4

- 2 intracellular "pools" of GLUT4
  - insulin-dependent (see cascade of Ins-receptor)
  - Ca^{2+} / NO / AMPK?-dependent
    - this mechanism is responsible for improvement of insulin sensitivity in physically active subjects

MUNI
MED

- hyperglycemia induces:
  - oxidative stress
  - endoplasmic reticulum (ER) stress
- high concentration of NEFA causes lipotoxicity
  - short term increase of NEFA stimulates secretion of insulin
  - long term exposure to NEFA, esp. long-chain saturated (e.g. palmitate), suppress secretion of insulin and damages B-cells
    - ↑ceramide → **apoptosis**

Obese or diabetic patient

FoxO1

Gluconeogenesis

Liver

Hyperglycemia

β cell apoptosis

Pancreas

Glucose production

Insulin secretion

Establishment of a vicious circle

ER stress → Unfolded protein response

- The unfolded protein response (UPR) is activated in response to an accumulation of unfolded or misfolded proteins in the lumen of ER
  - incl. insulin in β-cells
- UPR has two primary aims:
  - initially to restore normal function of the cell by halting protein translation and activate the signaling pathways that lead to increasing the production of molecular chaperones involved in protein folding
  - if these objectives are not achieved within a certain time lapse or the disruption is prolonged, the UPR aims to apoptosis

MUNI
MED

Overt T2DM

defect of postprandial glucose utilisation
(defect of GLUT4 translocation)

INSULIN

defect of gluconeogenesis suppression = fasting hyperglycemia
defect of suppression of VLDL formation = dyslipidemia

defect of lipolysis suppression
= overproduction of NEFA

NEFA interferes
with glucose utilization

NEFA interferes
with glucose utilization

- manifest T2DM is characterized by (variable degree of):
  - fasting hyperglycemia (due to gluconeogenesis)
    - **insulin resistance in liver**
  - postprandial hyperglycemia (due to decreased peripheral glucose uptake
    - **insulin resistance in muscle and adipose tissue**
  - mixed dyslipidemia
    - increased plasma NEFA (due to unsuppressed lipolysis)
      - **insulin resistance in adipose tissue**
    - pro-atherogenic dyslipidemia (due to stimulated VLDL production in liver)
      - **substrate effect**

MUNI
MED

Gestational diabetes mellitus (GDM)

- GDM develops during pregnancy (gestation) and it is one of the most common health problems of pregnancy
  - **up to 10%** of expectant mothers
- GDM is a serious problem because high blood sugar **affect both mother and offspring**
- GDM pathophysiology
  - hormonal changes in physiological pregnancy (i.e. **placental hormones**) cause mild **insulin resistance**
    - this is beneficial for the foetus and baby since glucose is the nutrient and insulin a growth hormone
    - placenta is ready and glucose-screening test is thus performed typically between 24 and 28 weeks
  - this requires additional insulin and normal pancreas can keep up with increased demands
  - if not, blood glucose levels rise too high, resulting in GDM
    - **risk factors**: age, overweight/obesity, susceptibility genes for T2DM, diet
- maternal hyperglycaemia stimulates **baby's pancreas to produce more insulin** to process the extra glucose
  - as a result baby can put on extra weight (**macrosomia**) with subsequent **complications during the birth** (shoulder dystocia, fractured bone or nerve damage)
    - hence the recommendation for early caesarean section
  - additionally, foetal hyperinsulinemia increases the risk of **post-delivery hypoglycaemia**
  - babies who have excessive fat stores as a result of high maternal sugar levels during pregnancy often continue to be overweight in childhood and adulthood (**foetal programming**)
- blood sugar usually returns to normal soon after delivery, however, GDM increases the **risk** for getting it again during the future pregnancy and for developing diabetes (**T2DM**) later in life (up to **50% post-GDM subjects**!!!)

Placenta

Oversized fetus

Other than type 1 and 2 forms of DM

- **LADA** (Latent Autoimmune Diabetes in Adults) = **slow-onset T1DM**
  - diagnosis in > 30yrs of age, clinically similar to T2DM (slow onset)
  - initially on diet and pills, no ketoacidosis
  - later insulin dependent (during months – 1 year)
  - positive antibodies (= autoimmunity), low or no C-peptide
  - negative family history of T2DM
- **MODY** (Maturity-onset diabetes of the young) – cca 5% T2DM
  - **monogenic** diabetes with familiar clustering and well defined (Mendelian) inheritance (usually AD), early manifestation (childhood or adolescence) and without obesity
  - 6 types (MODY1-6)
  - pathophysiology: genetically conditioned **dysfunction of β-cells** but long-term measurable C-peptide without the signs of autoimmunity
    - MODY due to **glucokinase** mutations (MODY2)
      - glucokinase = "glucose sensor" (impaired insulin secretion)
      - milder form without the complication risk
    - MODY due to **transcription factor** mutations (other 5 types)
      - severe defects of β-cells progressively leading to diabetes with complications
      - impairment of glucose-stimulated insulin secretion and proliferation and differentiation of β-cells

MODY	lokus	gen	produkt	prim. defekt	závaž	
.	. . .	*HNF4A*	hepatocyte nuclear factor-4α	pankreas	vysoká	časté
.	. .	*GCK*	glukokináza	pancreas/játra	mírná	vzácně
.	. . .	*TCF1 (HNF1A)*	hepatocyte nuclear factor-1α	pancreas/ledviny	vysoká	časté
.	. . .	*IPF1*	insulin promoter factor-1	pancreas	vysoká	?
5	17q	*TCF2 (HNF4B)*	hepatocyte nuclear factor-1β	pancreas/ledviny	vysoká	renální
6	2q32	*NEUROD1*	NEUROD1	pankreas	vysoká	?

MUNI
MED

T1DM

T1DM (formerly IDDM)

- selective autoimmune destruction of β cells of IofL in genetically predisposed individuals
- genetic susceptibility
  - chromosome 6 – MHC class III
    - DR3-DQ2 and DR4-DQ8
  - chromosome 11 - insulin gene
    - promotor polymorphism (variable length)
  - in both cases genetic background leads to insufficient deletion of autoreactive T-lymphocytes in thymus and therefore **suboptimal central immune (auto)tolerance**
- cytotoxic autoimmunity mediated by T-lymphocytes
  - there are also antibodies against β cell structures (ICA, GAD, IAA), but they are rather markers of autoimmunity than causal agents
- common association of T1DM with other autoimmune diseases
  - celiac disease
  - thyreopathy,
  - Addison syndrome

MUNI
MED

T1DM

- autoimmunity has to be triggered by various factors
  - infection
    - viruses
      - rubella, measles, coxsackie B, CMV, EBV, enteroviruses, retro-viruses
    - mechanism is unclear
      - cytolytic (⊗ sequestration of antigens
      - formation of neoantigens
      - molecular mimicry or superantigens
  - environmental factors (according to the epidemiologic evidence)
    - diet – early exposition proteins of cow's milk
      - bovine insulin
    - vitamin D – reason for **northern-southern geographical gradient**?
    - toxins (diet, water, bacteria)
    - gluten???
- manifestation typically in childhood
- absolute dependence on exogenous supplementation by insulin

Natural history of T1DM

a Early twentieth century

b Early twenty-first century

Number of cases

Degree of genetic or environmental contribution to T1DM (%)

Genetic factors   Environmental factors

Insulin treatment historically

2 tuny prasečích slinivek ⇒ cca 100g inzulinu

Insulin treatment nowadays (analogues)

Insulin treatment nowadays (analogues)

Main characteristics – comparison - of T1DM and T2DM

	T1DM	T2DM
onset	childhood	adults
genetic disposition	yes (oligogenic)	yes (polygenic)
clinical manifestation	often acute	mild or none
autoimmunity	yes	No
insulin resistance	no	yes
dependence on insulin	yes	No
obesity	no	yes

MUNI
MED

Acute manifestation and long-term consequences (complications) of diabetes

Q2: Effect of rising plasma glucose ???

OSMOLARITA = 2 Na$^+$ + urea + glukóza

275 - 295 = 2 x 140 + 2.5 + 5

> 300 = 2 x 140 + 2.5 + **35**

MUNI
MED

Clinical presentation of DM

- due to the mild increase of blood osmolarity, osmotic diuresis and dehydratation

  - classical
    - polyuria, thirst, polydipsia
    - tiredness
    - temporary impairment of vision
  - others
    - recurrent infections
    - perio-/parodontitis

- extreme hyperglycemia (>40 mmol/l, osmolarity >350 mosmol/l)

  - **ketoacidosis/coma**
    - $\uparrow$ ketone bodies, metabolic acidosis an d hyperglycemia
  - **non-ketoticidotic hyperglycemic coma**
    - hyperglycemia, dehydration and pre-renal uremia
  - **lactic acidosis/coma**
    - either complication of therapy (biguanides / type of peroral antidiabetics)
    - associated with hypoxic states (sepsis, shock, heart failure, …)

Diabetic ketoacidosis

- Excessive thirst
- Frequent urination
- Nausea and vomiting
- Abdominal pain
- Weakness or fatigue
- Shortness of breath
- Fruity-scented breath
- Confusion

Late complications of DM

- microvascular
  - diabetic retinopathy
  - diabetic nephropathy
    - diabetic kidney disease (DKD)
  - diabetic neuropathy
    - sensoric
    - motoric
    - autonomous

- macrovascular
  - accelerated atherosclerosis (CAD, peripheral and cerebrovascular vascular disease)
- combined
  - diabetic foot (ulcerations, amputations and Charcot´s joint)
- others
  - periodontitis
  - cataract
  - glaucoma

# Chronic hyperglycemia

Pathogenesis of complications

# Advanced glycation end products (AGEs)

- cross-linking of extracellular proteins
- modification of intracellular proteins and DNA
  - ubiquitin/proteasom
- binding to pattern-recognition receptors and activation of signaling pathways

Maillard reaction in food – AGEs in diet

- AGEs are similar to products of Maillard reaction (MRP) formed during thermal processing of food
  - sugar + protein
- Louis Camille Maillard (1878 - 1936)
  - original description of reactions during cooking ("browning") leading to formation of MRPs (=AGEs)
    - MRP influence taste and visual characteristics, smell, shelve life
  - biologic properties of MRP
    - positive – antioxidants
      - melanoidins, polyphenols
    - negative – carcinogens
      - acrylamid

Kinetics of AGEs in organism